OSI Pharmaceuticals updates OSI-774 Phase II data

In an ongoing Phase II trial of 56 patients with advanced, refractory non-small cell lung cancer (NSCLC), 150 mg of OSIP's OSI-774 oral epidermal growth factor receptor ( EGFR) inhibitor given once pe...